Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Gachon University Gil Medical Center95 enrolled

Overview

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Previous Treated Metastatic Non-small Cell Lung Cancer

Interventions

GefitinibDRUG

compare progression free survivla rate and safety to both drugs

PemetrexedDRUG

compare PFS rate, safety to both drugs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients * second line * ECOG 0～2 * Patients with normal liver function and renal function Exclusion Criteria: * Patients with severe acute infection requiring antibiotic therapy * Patients who have received treatment in other areas of cancer within 5 years * During pregnancy and lactation patients

Locations (1)

Gachon university Gil Medical Center

Incheon, South Korea

Outcomes

Primary Outcomes

Overall response rate

Time frame: 5 years

Secondary Outcomes

Progression free survival

Time frame: 5years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.